ANTITOXOPLASMA EFFECTS OF DAPSONE ALONE AND COMBINED WITH PYRIMETHAMINE

被引:39
作者
DEROUIN, F
PIKETTY, C
CHASTANG, C
CHAU, F
ROUVEIX, B
POCIDALO, JJ
机构
[1] HOP CLAUDE BERNARD,INSERM,F-75994 PARIS 19,FRANCE
[2] HOP ST LOUIS,DEPT BIOSTAT & INFORMAT MED,F-75475 PARIS 10,FRANCE
关键词
D O I
10.1128/AAC.35.2.252
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The efficacy of dapsone alone or combined with pyrimethamine against Toxoplasma gondii was investigated experimentally. For in vitro studies, a sensitive immunoassay was used for assessment of Toxoplasma growth in tissue cultures; dapsone was found to have a significant inhibitory effect at a concentration of 0.5-mu-g/ml in the cultures, and the 50% inhibitory concentration was estimated to be 0.55-mu-g/ml. When pyrimethamine and dapsone were combined, an important synergistic effect which was associated with morphological alterations of the parasites was observed. In vivo studies were performed in a murine model of acute toxoplasmosis in which a tissue culture method was used to estimate the parasite burden in the blood, lungs, and brains of infected mice. Dapsone alone, which was administered at 100 mg/kg/day for 10 days from day 1 after infection, was unable to prevent parasite dissemination and only delayed the time of death of treated mice compared with the time of death of untreated controls. When dapsone and pyrimethamine (18.5 mg/kg/day) were administered in combination from day 4 after infection, parasites were cleared from blood and organs within 6 days, but relapses were observed 15 days after the cessation of therapy. When treatment was started at day 1 after infection, 100% of mice survived and relapses were not observed, suggesting a good efficacy of this combination for preventive therapy.
引用
收藏
页码:252 / 255
页数:4
相关论文
共 15 条
[1]   PHARMACOKINETICS AND PROTEIN-BINDING INTERACTIONS OF DAPSONE AND PYRIMETHAMINE [J].
AHMAD, RA ;
ROGERS, HJ .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1980, 10 (05) :519-524
[2]   INTERACTION OF SULFONAMIDE AND SULFONE COMPOUNDS WITH TOXOPLASMA-GONDII DIHYDROPTEROATE SYNTHASE [J].
ALLEGRA, CJ ;
BOARMAN, D ;
KOVACS, JA ;
MORRISON, P ;
BEAVER, J ;
CHABNER, BA ;
MASUR, H .
JOURNAL OF CLINICAL INVESTIGATION, 1990, 85 (02) :371-379
[3]   INVITRO EFFECTS OF FOLATE INHIBITORS ON TOXOPLASMA-GONDII [J].
DEROUIN, F ;
CHASTANG, C .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1989, 33 (10) :1753-1759
[5]  
GARG SK, 1988, INT J CLIN PHARM TH, V26, P552
[6]   EFFICACY OF DIAMINODIPHENYLSULFONE AND OTHER DRUGS IN MURINE PNEUMOCYSTIS-CARINII PNEUMONITIS [J].
HUGHES, WT ;
SMITH, BL .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1984, 26 (04) :436-440
[7]   DAPSONE, TRIMETHOPRIM, AND SULFAMETHOXAZOLE PLASMA-LEVELS DURING TREATMENT OF PNEUMOCYSTIS PNEUMONIA IN PATIENTS WITH THE ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS) - EVIDENCE OF DRUG-INTERACTIONS [J].
LEE, BL ;
MEDINA, I ;
BENOWITZ, NL ;
JACOB, P ;
WOFSY, CB ;
MILLS, J .
ANNALS OF INTERNAL MEDICINE, 1989, 110 (08) :606-611
[8]   PRIMARY DAPSONE CHEMOPROPHYLAXIS FOR PNEUMOCYSTIS-CARINII PNEUMONIA IN IMMUNOCOMPROMISED PATIENTS INFECTED WITH THE HUMAN IMMUNODEFICIENCY VIRUS [J].
LUCAS, CR ;
SANDLAND, AM ;
MIJCH, A ;
SIMPSON, JM .
MEDICAL JOURNAL OF AUSTRALIA, 1989, 151 (01) :30-33
[9]   DAPSONE TREATMENT OF PNEUMOCYSTIS-CARINII PNEUMONIA IN THE ACQUIRED IMMUNODEFICIENCY SYNDROME [J].
MILLS, J ;
LEOUNG, G ;
MEDINA, I ;
HOPEWELL, PC ;
HUGHES, WT ;
WOFSY, C .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1988, 32 (07) :1057-1060
[10]  
OHSIMA S, 1969, AM J TROP MED HYG, V19, P422